Related Experiment Video
Updated: Jun 28, 2026
06:25
Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
Published on: March 29, 2024
The type 1 insulin-like growth factor receptor pathway
Meenali M Chitnis1, John S P Yuen, Andrew S Protheroe
1Department of Medical Oncology, Churchill Hospital, Oxford, UK.
Summary
The type 1 insulin-like growth factor receptor (IGF1R) is crucial in cancer growth and treatment resistance. Targeting IGF1R shows promise for new cancer therapies, with ongoing clinical trials evaluating its effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The type 1 insulin-like growth factor receptor (IGF1R) plays a significant role in cancer development, metastasis, and therapy resistance.
- IGF1R is a validated therapeutic target, despite challenges in drug design due to normal tissue expression and homology with the insulin receptor.
Purpose of the Study:
- To review the signaling pathways regulated by IGF1R.
- To summarize preclinical data supporting IGF1R as a cancer treatment target.
- To discuss clinical progress, potential toxicities, and combination strategies for IGF1R inhibitors.
Main Methods:
- Review of preclinical research validating IGF1R as a therapeutic target.
- Analysis of ongoing clinical trials for IGF1R inhibitory drug candidates.
- Examination of IGF1R signaling pathways and their role in cancer.
Main Results:
- Approximately 12 anti-IGF1R therapeutics, including antibodies and kinase inhibitors, are in clinical trials.
- Preclinical data strongly support IGF1R as a viable target for cancer therapy.
- Understanding IGF1R signaling is essential for identifying patient populations likely to benefit from treatment.
Conclusions:
- IGF1R inhibition is a promising strategy for cancer treatment.
- Careful patient selection using molecular markers is crucial for successful clinical translation.
- Further research is needed to optimize combination therapies and manage potential toxicities.
More Related Videos
Related Concept Videos
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...